We appreciate the constructive commentary by Dr Paul Corris and colleagues1 that highlights the merits and limitations of our manuscript. A recent editorial from Dr Vincent Cottin requested that clinical trials, in the setting of pulmonary fibrosis (PF)-associated pulmonary hypertension (PH), ‘should first be conducted in subjects with disproportionate elevation of pulmonary vascular resistance as compared to the severity of pulmonary fibrosis…in whom PH likely contributes the most to exercise limitation and morbidity’.2

In this spirit, the purpose of our study is to emphasise the inclusion of a specific, although less common PF-PH phenotype (excluding sarcoidosis and scleroderma) with advanced pulmonary haemodynamics …